GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (SZSE:300759) » Definitions » Debt-to-Asset

Pharmaron Beijing Co (SZSE:300759) Debt-to-Asset : 0.33 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Debt-to-Asset?

Pharmaron Beijing Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥864 Mil. Pharmaron Beijing Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥7,388 Mil. Pharmaron Beijing Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ¥25,244 Mil. Pharmaron Beijing Co's debt to asset for the quarter that ended in Mar. 2024 was 0.33.


Pharmaron Beijing Co Debt-to-Asset Historical Data

The historical data trend for Pharmaron Beijing Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Debt-to-Asset Chart

Pharmaron Beijing Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.09 0.29 0.30 0.37

Pharmaron Beijing Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.27 0.28 0.37 0.33

Competitive Comparison of Pharmaron Beijing Co's Debt-to-Asset

For the Biotechnology subindustry, Pharmaron Beijing Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaron Beijing Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's Debt-to-Asset falls into.



Pharmaron Beijing Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Pharmaron Beijing Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(912.728 + 8784.863) / 26476.713
=0.37

Pharmaron Beijing Co's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(864.465 + 7388.346) / 25243.967
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaron Beijing Co  (SZSE:300759) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Pharmaron Beijing Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaron Beijing Co (SZSE:300759) Business Description

Traded in Other Exchanges
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.
Executives
Lou Xiao Qiang Directors, executives
Zheng Bei Directors, executives

Pharmaron Beijing Co (SZSE:300759) Headlines

No Headlines